Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEVEN F WEINSTEIN

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1518035120
CMS profile
67812
Location
HUNTINGTON BEACH, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$6,801.51

69 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $3,438.00 2
Food and Beverage $2,271.44 61
Travel and Lodging $1,058.07 5
Education $34.00 1

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 2; records 51–69 of 69 matching records. This page contains 19 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEVEN F WEINSTEIN

NPI 1518035120 · CMS profile ID 67812

Allopathic & Osteopathic Physicians / Allergy & Immunology

HUNTINGTON BEACH, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–69 of 69 matching records. This page contains 19 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1518035120?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEVEN F WEINSTEIN, NPI 1518035120, CMS profile ID 67812. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–69 of 69 matching records. This page contains 19 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1518035120?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). STEVEN F WEINSTEIN, NPI 1518035120, CMS profile ID 67812. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–69 of 69 matching records. This page contains 19 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1518035120?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
STEVEN F WEINSTEIN, NPI 1518035120, CMS profile ID 67812, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–69 of 69 matching records. This page contains 19 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1518035120?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

69 matching records · $6,801.51 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 69 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–69 of 69.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Healthcare Solutions, Inc. $94.3604/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213069408 CMS
Regeneron Healthcare Solutions, Inc. $60.0004/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213069410 CMS
Regeneron Healthcare Solutions, Inc. $150.0004/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213069412 CMS
Regeneron Healthcare Solutions, Inc. $387.3604/26/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1213069414 CMS
ALK-Abello, Inc $32.9004/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222418024 CMS
AstraZeneca Pharmaceuticals LP $20.0204/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206219794 CMS
CSL Behring $35.6604/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232344598 CMS
Amgen Inc. $8.8003/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227153901 CMS
Regeneron Healthcare Solutions, Inc. $18.2803/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213069402 CMS
Cycle Pharmaceuticals Inc $13.5603/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248902888 CMS
GlaxoSmithKline, LLC. $14.8103/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191723197 CMS
PFIZER INC. $22.5503/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231450379 CMS
Amgen Inc. $111.0003/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228327286 CMS
ARS Pharmaceuticals Operations, Inc. $29.2902/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1245896831 CMS
Takeda Pharmaceuticals U.S.A., Inc. $18.4202/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223843977 CMS
Regeneron Healthcare Solutions, Inc. $31.9001/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213069400 CMS
GlaxoSmithKline, LLC. $11.4601/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191244152 CMS
GlaxoSmithKline, LLC. $34.3401/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191303513 CMS
Amgen Inc. $9.1201/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227153899 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $21,170.38 49
PY2020 $7,064.45 18
PY2021 $2,424.53 23
PY2022 $4,174.97 36
PY2023 $4,556.25 40
PY2024 $192,489.89 30
PY2025 $6,801.51 69

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $59,566.70 15
PY2025 Principal investigator $573,854.27 39
PY2024 Principal investigator $203,979.11 23
PY2023 Recipient $13,500.00 1
PY2023 Principal investigator $251,920.60 80
PY2022 Recipient $2,489.67 3
PY2022 Principal investigator $442,313.77 19
PY2021 Principal investigator $155,110.13 25
PY2020 Principal investigator $395,325.56 47
PY2019 Recipient $80.50 1
PY2019 Principal investigator $743,674.98 69

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

54 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $686.66 12/19/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244045938
Recipient GENZYME CORPORATION $15,619.00 12/10/2025 Covered Recipient Physician A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226080300
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,848.99 12/03/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244045940
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $620.40 12/01/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244045942
Principal investigator 1 Novartis Pharmaceuticals Corporation $22.58 11/15/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS MEDICAL GROUP AND RESEARCH CT
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Remibrutinib (LOU064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihi No dispute reported 06/30/2026 1190302709
Principal investigator 1 AstraZeneca Pharmaceuticals LP $44,974.65 10/08/2025 Non-covered Recipient Entity
STEVEN WEINSTEIN DBA ALLERGY AND ASTHMA SPECIALISTS MEDICAL
A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma No dispute reported 06/30/2026 1185540255
Recipient GENZYME CORPORATION $515.42 10/03/2025 Covered Recipient Physician A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226080296
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $34,087.84 10/03/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244046226
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,943.56 08/15/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244046228
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $27,190.92 08/06/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244046230
Principal investigator 1 Novartis Pharmaceuticals Corporation $85,057.10 08/01/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS GROUP
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190306201
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $143.92 07/31/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244045858
Principal investigator 1 AstraZeneca Pharmaceuticals LP $23,354.47 07/29/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 1185540251
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $71.96 07/18/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244045864
Recipient GENZYME CORPORATION $4,198.00 07/14/2025 Covered Recipient Physician A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226080288
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $35.98 07/10/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244045856
Principal investigator 1 Eli Lilly and Company $32,116.98 07/09/2025 Non-covered Recipient Entity
STEVEN F WEINSTEIN MD A PROFES
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB/ LY3650150 IN ADULT PARTICIPANTS WITH PERENNIAL ALLERGIC RHINITIS No dispute reported 06/30/2026 1187890712
Recipient GENZYME CORPORATION $9,434.57 07/07/2025 Covered Recipient Physician A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226080285
Recipient GENZYME CORPORATION $879.00 06/27/2025 Covered Recipient Physician A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226080292
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $35.98 06/17/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244045866
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $35.98 06/06/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244045854
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $33.32 05/28/2025 Non-covered Recipient Individual A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244045416
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $70.00 05/28/2025 Non-covered Recipient Individual A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244045554
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $43.80 05/28/2025 Non-covered Recipient Individual A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244045556
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $27.33 05/28/2025 Non-covered Recipient Individual A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244045558
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8.89 05/28/2025 Non-covered Recipient Individual A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244045560
Recipient GENZYME CORPORATION $586.00 05/27/2025 Covered Recipient Physician A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226080281
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,847.00 05/16/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244046446
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,500.00 05/09/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244046444
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,505.00 05/08/2025 Non-covered Recipient Entity
STEVEN WEINSTEIN DBA ALLERGY AND ASTHMA SPECIALISTS MEDICAL
A Phase 2 randomized double blind placebo controlled dose regimen range finding study to assess efficacy and safety of subcutaneous tozorakimab in adult participants with uncontrolled asthma on medium to high dose inhaled corticosteroids No dispute reported 06/30/2026 1185540257
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,000.00 05/08/2025 Non-covered Recipient Entity
Allergy and Asthma Specialists Medical Group and Research Center
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048662
Principal investigator 1 AstraZeneca Pharmaceuticals LP $9,450.00 05/07/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
A Phase 2 randomized double blind placebo controlled dose regimen range finding study to assess efficacy and safety of subcutaneous tozorakimab in adult participants with uncontrolled asthma on medium to high dose inhaled corticosteroids No dispute reported 06/30/2026 1185540249
Principal investigator 1 AstraZeneca Pharmaceuticals LP $131,700.83 05/02/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma No dispute reported 06/30/2026 1185540259
Principal investigator 1 AstraZeneca Pharmaceuticals LP $101,216.38 05/01/2025 Non-covered Recipient Entity
STEVEN WEINSTEIN DBA ALLERGY AND ASTHMA SPECIALISTS MEDICAL
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 1185540261
Recipient GENZYME CORPORATION $26,189.00 04/11/2025 Covered Recipient Physician A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226080277
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $204.60 04/08/2025 Non-covered Recipient Entity
Allergy and Asthma Specialists Medical Group and Research Center
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244048686
Principal investigator 1 AstraZeneca Pharmaceuticals LP $6,422.68 04/03/2025 Non-covered Recipient Entity
STEVEN WEINSTEIN DBA ALLERGY AND ASTHMA SPECIALISTS MEDICAL
A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1185540247
Principal investigator 1 CIPLA USA INC. $600.00 04/02/2025 Non-covered Recipient Entity
TTS RESEARCH
A RANDOMIZED, SINGLE-DOSE, DOUBLE-BLIND, PLACEBO-CONTROLLED, FOUR-WAY CROSSOVER, MULTICENTER BRONCHOPROVOCATION STUDY COMPARING THE BRONCHOPROTECTIVE EFFECTS OF ALBUTEROL SULFATE INHALATION AEROSOL (90 MCG, INVAGEN/CIPLA) WITH VENTOLIN HFA (90 MCG, GLAXOSMITHKLINE) IN ADULT ASTHMA PATIENTS. No dispute reported 06/30/2026 1254932227
Principal investigator 1 CIPLA USA INC. $1,200.00 04/01/2025 Non-covered Recipient Entity
ORANGE COUNTY ALLERGY & ASTHMA SPECIALISTS MEDICAL GROUP
A RANDOMIZED, SINGLE-DOSE, DOUBLE-BLIND, PLACEBO-CONTROLLED, FOUR-WAY CROSSOVER, MULTICENTER BRONCHOPROVOCATION STUDY COMPARING THE BRONCHOPROTECTIVE EFFECTS OF ALBUTEROL SULFATE INHALATION AEROSOL (90 MCG, INVAGEN/CIPLA) WITH VENTOLIN HFA (90 MCG, GLAXOSMITHKLINE) IN ADULT ASTHMA PATIENTS. No dispute reported 06/30/2026 1254932251
Principal investigator 1 AstraZeneca Pharmaceuticals LP $6,861.52 03/28/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1185540253
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $215.88 03/27/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244046058
Principal investigator 1 Novartis Pharmaceuticals Corporation $17,102.38 02/27/2025 Non-covered Recipient Entity
STEVEN F WEINSTEIN ALLERGY AND ASTHMA SPECIALISTS MEDICALX GROUP
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately co No dispute reported 06/30/2026 1190300609
Recipient Teva Pharmaceuticals USA, Inc. $81.00 02/21/2025 Covered Recipient Physician A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244039993
Recipient Teva Pharmaceuticals USA, Inc. $7.00 02/19/2025 Covered Recipient Physician A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244039995
Recipient Teva Pharmaceuticals USA, Inc. $23.40 02/19/2025 Covered Recipient Physician A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244039997
Recipient Teva Pharmaceuticals USA, Inc. $261.01 02/19/2025 Covered Recipient Physician A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244039999
Recipient Teva Pharmaceuticals USA, Inc. $163.86 02/19/2025 Covered Recipient Physician A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244040005
Recipient Teva Pharmaceuticals USA, Inc. $23.40 02/19/2025 Covered Recipient Physician A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244040007
Recipient Teva Pharmaceuticals USA, Inc. $195.71 02/18/2025 Covered Recipient Physician A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244040001
Recipient Teva Pharmaceuticals USA, Inc. $1,390.33 02/18/2025 Covered Recipient Physician A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244040003
Principal investigator 1 Novartis Pharmaceuticals Corporation $112.90 01/15/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS MEDICAL GROUP AND RESEARCH CT
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Remibrutinib (LOU064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihi No dispute reported 06/30/2026 1190302711
Principal investigator 1 CIPLA USA INC. $2,000.00 01/07/2025 Non-covered Recipient Entity
TTS RESEARCH
A RANDOMIZED, SINGLE-DOSE, DOUBLE-BLIND, PLACEBO-CONTROLLED, FOUR-WAY CROSSOVER, MULTICENTER BRONCHOPROVOCATION STUDY COMPARING THE BRONCHOPROTECTIVE EFFECTS OF ALBUTEROL SULFATE INHALATION AEROSOL (90 MCG, INVAGEN/CIPLA) WITH VENTOLIN HFA (90 MCG, GLAXOSMITHKLINE) IN ADULT ASTHMA PATIENTS. No dispute reported 06/30/2026 1254932225
Principal investigator 1 CIPLA USA INC. $14,942.07 01/07/2025 Non-covered Recipient Entity
ORANGE COUNTY ALLERGY & ASTHMA SPECIALISTS MEDICAL GROUP
A RANDOMIZED, SINGLE-DOSE, DOUBLE-BLIND, PLACEBO-CONTROLLED, FOUR-WAY CROSSOVER, MULTICENTER BRONCHOPROVOCATION STUDY COMPARING THE BRONCHOPROTECTIVE EFFECTS OF ALBUTEROL SULFATE INHALATION AEROSOL (90 MCG, INVAGEN/CIPLA) WITH VENTOLIN HFA (90 MCG, GLAXOSMITHKLINE) IN ADULT ASTHMA PATIENTS. No dispute reported 06/30/2026 1254932249
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,561.72 01/01/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS GROUP
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately co No dispute reported 06/30/2026 1190306203